

1 **Optimal age targeting for pneumococcal vaccination in older adults; a**  
2 **modelling study.**

3  
4 **Authors:**

5 Deus Thindwa, MSc <sup>1,2,3</sup>, Samuel Clifford, PhD <sup>1,2</sup>, Jackie Kleynhans, MSc <sup>4,5</sup>, Prof Anne von  
6 Gottberg, PhD <sup>4,6</sup>, Sibongile Walaza, PhD <sup>4</sup>, Susan Meiring, MBChB <sup>4</sup>, Todd D Swarthout, PhD  
7 <sup>3,7</sup>, Prof Elizabeth Miller, FMedSci<sup>2</sup>, Prof Peter McIntyre, D Med Sc <sup>9</sup>, Prof Nick Andrews, PhD  
8 <sup>8</sup>, Zahin Amin-Chowdhury, PhD <sup>8</sup>, Norman Fry, PhD <sup>8</sup>, Kondwani Jambo, PhD <sup>3,10</sup>, Prof Neil  
9 French, PhD <sup>3,11</sup>, Samanta Cristine Grassi Almeida, PhD <sup>12</sup>, Prof Shamez Ladhani, PhD <sup>8</sup>, Prof  
10 Robert S Heyderman, PhD <sup>3,7</sup>, Prof Cheryl Cohen, PhD <sup>4,5</sup>, Prof Maria Cristina de Cunto  
11 Brandileone, PhD <sup>12</sup>, Prof Stefan Flasche, PhD <sup>1,2</sup>.

12  
13 **Institutions:**

14 <sup>1</sup> Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene &  
15 Tropical Medicine, London, UK

16 <sup>2</sup> Department of Infectious Disease Epidemiology London School of Hygiene & Tropical  
17 Medicine, London, UK

18 <sup>3</sup> Malawi Liverpool Wellcome Research Programme, Blantyre, Malawi

19 <sup>4</sup> Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases  
20 of the National Health Laboratory Service, Johannesburg, South Africa

21 <sup>5</sup> School of Public Health, University of the Witwatersrand, Johannesburg, South Africa

22 <sup>6</sup> School of Pathology, University of the Witwatersrand, Johannesburg, South Africa

23 <sup>7</sup> Division of Infection and Immunity, University College London, London, UK

24 <sup>8</sup> Immunisation and Countermeasures Division, UK Health Security Agency, London, UK

25 <sup>9</sup> University of Otago, Dunedin, New Zealand

26 <sup>10</sup>Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.

27 <sup>11</sup> Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, UK

28 <sup>12</sup> National Laboratory for Meningitis and Pneumococcal Infections, Laboratory for Meningitis,

29 Pneumonia and Pneumococcal Infection, Centre of Bacteriology, Brazil

30

31 **Corresponding author:**

32 \*Email: [deus.thindwa@lshtm.ac.uk](mailto:deus.thindwa@lshtm.ac.uk)

33 Phone: +265997788370

34 Malawi Liverpool Wellcome Research Programme, Blantyre, Malawi & Department of

35 Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel

36 Street, London, UK

37

## 38 **Abstract**

### 39 **Background**

40 Invasive pneumococcal disease (IPD) risk increases with age for older adults whereas the  
41 population size benefiting from pneumococcal vaccines and the robustness of the immunogenic  
42 response to vaccination decline. This poses a conundrum for identifying the optimal age for  
43 vaccination. We estimate how demographics, vaccine efficacy/effectiveness (VE), and waning  
44 VE impact on optimal age for single-dose pneumococcal vaccination.

### 46 **Methods**

47 Age- and vaccine-serotype-stratified IPD incidence from routine surveillance of adults  $\geq 55$  years  
48 old (y) in Brazil, England, Blantyre (Malawi), and South Africa,  $\geq 4$ -years after infant-  
49 pneumococcal vaccine introduction and before 2020, was used to parameterise exponential  
50 growth models of increasing IPD risk with age. A piecewise-constant model estimated VE and  
51 waning VE from prior studies. All estimates were then combined in a cohort model to assess the  
52 vaccine preventable IPD burden of delivering 13-, 15-, 20-valent conjugate or 23-valent  
53 polysaccharide vaccines at various ages.

### 55 **Findings**

56 In Brazil, Malawi, South Africa and England 51%, 51%, 54% and 39% of adults older than 55y  
57 were younger than 65y old. A smaller share of IPD was reported among adults  $< 65$ y old in  
58 England (4,657 annual cases; 20%  $< 65$ y) compared to Brazil (186; 45%), Malawi (4; 63%), or  
59 South Africa (134, 48%). PCV13- and PPV23-serotypes were estimated to cause 39% and 85%  
60 of IPD cases on average across settings. Vaccination at 55y in Brazil, Malawi, and South Africa,

61 and at 70y in England had the greatest potential for IPD prevention with 38%, 31%, 27%, 8% of  
62 IPD preventable if using PCV13, 44%, 32%, 30%, 13% with PCV15, 65%, 69%, 53%, 37% with  
63 PCV20, and 30%, 29%, 20%, 14% with PPV23, respectively. Vaccination efficiency or cost  
64 effective use was optimal in 60-65y in Brazil, Malawi and South Africa, and in 80-85y in  
65 England.

66

### 67 **Interpretation**

68 In low/middle-income countries, pneumococcal vaccines may prevent a substantial proportion of  
69 the residual IPD burden if administered earlier in adulthood than is typical in high-income  
70 countries.

71

### 72 **Funding**

73 UK National Institute for Health and Care Research.

74

## 75 **Research in context**

76 Evidence before this study

77 A recent review conducted for the World Health Organisation (WHO) Scientific Advisory Group  
78 of Experts (SAGE) working group on pneumococcal vaccines reviewed the evidence on the  
79 efficacy, effectiveness and potential impact of pneumococcal vaccines in older adults. At the  
80 time, little evidence was identified to support recommendations for the age of pneumococcal  
81 vaccination in older adults, particularly in LMICs. We did an updated search of PubMed,  
82 Medline, Embase and Web of Science for studies on age targeting for pneumococcal vaccination  
83 in older adults published from Jan 1, 2003 to June 30, 2022, using the search terms “(optimal age  
84 targeting OR age targeting OR timeliness) AND (pneumococcal vaccination OR pneumococcal  
85 vaccines) AND (adults OR older adults OR elderly)”. We identified one study on the role of  
86 timeliness in the cost-effectiveness of older adult vaccination in Australia. This study explored  
87 the impact of the timeliness of pneumococcal conjugate vaccination (PCV) in older adults and  
88 found that more hospitalisations and deaths can be prevented if PCV13 was given to 70y old than  
89 as recommended at 65y. On the other hand, most low-income countries (LICs) and middle-  
90 income countries (MICs) do not have routine older adult pneumococcal vaccination programmes,  
91 despite often less indirect protection from childhood PCV programmes and high burden of  
92 vaccine preventable disease. The implications of differences in population demographics and risk  
93 for IPD compared to high income countries on the optimal age for pneumococcal vaccination in  
94 LICs/MICs are unknown.

95

96 Added value of this study

97 This multicountry study uses data from long-standing older adult pneumococcal surveillance  
98 programmes at the national/sub-national level, to explore the optimal age-targeting for a single-  
99 dose pneumococcal vaccination against vaccine-serotype-IPD in older adults living without  
100 human immunodeficiency virus in LIC (Malawi), MICs (Brazil, South Africa), and HIC  
101 (England). We show that despite mature pneumococcal infant vaccination programmes there is a  
102 substantial burden of vaccine preventable pneumococcal disease remaining in the four countries  
103 considered. Vaccinating at 55y in the LICs/MICs was optimal whereas vaccinating at 70y  
104 prevented most IPD cases in England than vaccinating at other ages. While the number of older  
105 adults needed to vaccinate to prevent an IPD case may be higher for programmes vaccinating  
106 older individuals, vaccination efficiency or vaccine cost effective use was optimal in 60-65y in  
107 LICs/MICs, and in 80-85y in England.

108

109 Implications of all available evidence

110 LICs/MICs with a mature infant immunisation programme for pneumococci and a remaining  
111 high burden of vaccine preventable pneumococcal disease in older adults may consider  
112 implementation of a vaccination programme for older adults, albeit at a younger age than typical  
113 in HICs. Affordability and cost-effectiveness of an adult vaccination programme as well as the  
114 indirect effects following potential changes to higher valency infant PCV vaccination  
115 programmes will also need to be considered.

116

## 117 **Introduction**

118 *Streptococcus pneumoniae* (pneumococcus) is a major global cause of childhood mortality [1,2],  
119 but also causes a high burden of disease among older adults [2,3]. Two vaccines have been used  
120 to prevent pneumococcal disease in older adults  $\geq 55$  years-old (y): a 13-valent pneumococcal  
121 conjugate vaccine (PCV13) and a 23-valent pneumococcal polysaccharide vaccine (PPV23) [4].  
122 Recently, 15- and 20-valent PCVs (PCV15, PCV20) have also been licensed and recommended  
123 for older adults in the United States [5,6].

124  
125 Although routine infant PCV programmes have generated indirect protection against vaccine-  
126 serotype (VT) pneumococcal disease among older adults [7,8], a substantial disease burden  
127 remains, composed of serotypes not targeted by childhood PCV programmes and residual  
128 circulation of VT [2,9]. Among high-income countries (HICs) with a mature infant-PCV13  
129 programme, PCV13- and PPV23-targeted serotypes caused about 15% and 42%, respectively, of  
130 invasive pneumococcal disease (IPD) in older adults [2,10]. Routine infant-PCV programmes in  
131 many low- and middle-income countries (LICs and MICs) have often led to less pronounced  
132 herd effects with continued circulation of VTs especially in the unvaccinated adult population  
133 [11,12], who happen to have no access to routine pneumococcal vaccination [13].

134  
135 The recommended age for pneumococcal vaccination in older adults in HICs is typically either at  
136 60y or 65y [4,14]. However, yet only a single study has assessed the age at which the most gain  
137 from such programme is seen (in the Australian context) [15]. As the risk of severe  
138 pneumococcal disease increases with age [10,15], waning of protection from vaccination early in  
139 older adulthood risks disease at ages of highest disease incidence, whereas vaccination late in

140 older adulthood cannot address the substantial disease burden among a large pool of susceptible  
141 older adults who have not yet been vaccinated.

142  
143 In this modelling study, we explore the optimal age-targeting for a single-dose pneumococcal  
144 vaccination against VT-IPD in older adults living without human immunodeficiency virus (HIV)  
145 in Brazil, England, Malawi, and South Africa.

146

## 147 **Methods**

### 148 **Study sites**

149 We included England (HIC), Brazil and South Africa (MICs), and Blantyre in Malawi (LIC) in  
150 this analysis, to explore the optimal age-targeting for pneumococcal vaccination, as all have  
151 long-standing adult pneumococcal surveillance programmes at the national or sub-national level  
152 [9,16–18]. More details on the respective IPD surveillance systems are in the appendix (Text  
153 S1). Infant-PCV13 has been in use since 2011 in South Africa (two primary doses and booster  
154 (2+1) schedule) and Malawi (3+0 schedule), with estimated 90-95% vaccination coverage  
155 [11,18]. In England, routine PCV13 immunisation programme with 92% booster dose coverage  
156 has been in place since 2010, initially using a 2+1 schedule, switching to 1+1 schedule in 2020  
157 [19]. In Brazil, a routine infant-PCV10 programme was implemented in 2010 with a 3+1  
158 schedule, switched to a 2+1 in 2016, with average coverage of 94% between 2015 and 2017 [20].

159

160 In England, PPV23 has been recommended for risk groups since 1992, and for all adults aged  
161  $\geq 65$ y since 2003, with single-dose coverage rising to 70% in 2018 [17,21]. In Brazil, PPV23 is  
162 not included in the national immunisation programme but has been recommended for use since



163 the 1980s, and is available free of charge at the centers of special immunobiological for people  
164 above 2 years old including institutionalised older adult, and thus coverage of <1% among all  
165 older adults above 60y [22]. In South Africa, although adult pneumococcal vaccination is  
166 recommended, there is no routine programme nor nationally accepted guidelines [23]. In  
167 Malawi, neither routine adult pneumococcal vaccination programme nor national guidelines exist  
168 [13].

169

### 170 **Population demographics**

171 The population demographics for adults  $\geq 55y$  were obtained in annual age strata from population  
172 censuses conducted in 2010 for Brazil [24], 2011 England (updated in 2017) [25], 2018 Malawi  
173 [26], and 2011 South Africa [27]. To align with IPD surveillance timelines in respective  
174 countries, annual age population censuses were projected at a constant growth rate of 0.8%  
175 during 2010-2016 in Brazil and 1.3% during 2011-2016 in South Africa [28,29]. For England  
176 and Malawi, 2017 and 2018 populations already aligned with IPD surveillance time. Annual age  
177 population estimates were smoothed to reduce demographic stochasticity in downstream results  
178 by applying a 5-year moving average [30].

179

### 180 **Invasive pneumococcal disease burden**

181 For each site we used data on IPD burden in older adults in the presence of a mature infant-PCV  
182 programme, defined as at least 4 years after infant-PCV introduction, to avoid inclusion of  
183 ongoing changes in IPD burden attributable to indirect effects from the childhood programme  
184 [31]. The number of IPD cases caused by all serotypes, and serotypes targeted by PCV13,  
185 PCV15, PCV20 and PPV23 in annual age strata (55y to 85y+) were obtained from laboratory-

186 based surveillance in each country (Fig S1). We calculated age and serotype distribution and  
187 proportionally inflated estimates by the number of IPD cases without serotyping available to  
188 correct for proportion serotyped. In England, where PPV23 has been in use in 65y+ at 70%  
189 uptake, we back-inflated the number of IPD cases in order to correct for the fact that in the  
190 absence of PPV23 vaccination, IPD incidence would be higher, especially in ages eligible for  
191 PPV23 vaccination. Details about back-inflation calculation are in the appendix (Text S2). Age  
192 aggregated (55-59y, 60-64y, 65-69y, 70-74y, 75-79y, 80-84y and 85y+) and serotype-specific  
193 IPD incidence was calculated by dividing by the age-group specific population estimates. Due to  
194 the small number of reported IPD cases and incomplete serotyping information in Malawi, we  
195 only calculated the serotype distribution for all cases and assumed that it was the same in each  
196 age group.

197  
198 The focus of this study was vaccination strategies for older adults living without HIV because  
199 adults living with HIV often have independent pneumococcal vaccine recommendations [12].  
200 Thus, for adult HIV prevalence of >10% in South Africa [32], we adjusted IPD incidence  
201 estimates for HIV status. For 201 (18.7%) reported IPD cases, HIV status was reported. We took  
202 a 30% random subset of IPD cases with known HIV status and estimated a 49.3% proportion of  
203 IPD cases without HIV for this subset. We assumed that a similar proportion of IPD cases with  
204 unknown HIV status would be without HIV. We further accounted for similar serotype  
205 distribution in those with and without HIV. In Malawi, IPD cases could not be stratified by HIV  
206 infection status, and thus we used the age-dependent HIV infection rates in the general adult  
207 population and applied the relative propensity for IPD in older adults with and without HIV from  
208 South Africa to infer the incidence of IPD among older adults without HIV by age.

209

210 We modelled the reported age-specific IPD incidence among older adults without HIV per  
211 country as a function of age using an exponential growth model. Details about model fitting are  
212 in appendix (Text S3). The expected incidence at age  $a$  is:

213

$$E(I|a) = \gamma e^{\beta a} \dots \dots \dots (1),$$

214 where  $E(I|a)$  is the expected IPD incidence at age  $a$ ,  $\beta$  is the growth rate, and  $\gamma$  is a constant of  
215 proportionality. Uncertainty was obtained by bootstrap sampling 1000 times using the fitted  
216 parameter means and covariance matrix and summarisation of uncertainty via 95% quantiles of  
217 samples.

218

### 219 **PCV and PPV vaccine efficacy/effectiveness**

220 A previous systematic review identified studies that estimate vaccine efficacy/effectiveness (VE)  
221 against IPD from time since vaccination [2]. Four observational studies in HICs estimated VE at  
222 two or more time points for PPV23 [17,21,33–35]. One randomised controlled trial estimated VE  
223 against IPD and community-acquired pneumonia (CAP) following PCV13 use in older adults  
224 and found consistent 75% and 46% respective efficacy for 5 years following vaccination [36,37].  
225 Thus, we assumed that PCVs' efficacy against IPD would continue to stay stable for five years,  
226 and thereafter decline in the same way as the scenario for PPV23. We represented the VE as a  
227 function of time since vaccination using piecewise constant models. The piecewise constant  
228 functions are shown in appendix (Fig S2, Fig S3). The VE was sampled using bootstrap  
229 sampling from a normal distribution centred on the mean VE at that time and standard deviation  
230 derived from the reported 95% interval.

231  
232 Little evidence is available on changes in PPV23 or PCV13 VE by age at administration [15,38].  
233 A UK study found no significant difference in VE of PPV23 when administered to 65y, 75y or  
234 85y adults, although point estimates suggested a decline with age [17]. There is also some  
235 evidence that immune response to immunisation is partially impaired later in life [2]. Thus, as a  
236 base case we assumed that VE for all formulations was independent of the age of administration,  
237 but included a sensitivity analysis assuming that VE was 33% less of initial VE if given to adults  
238 aged 65-74y and 44% less of initial VE if given to adults aged 75+y using point estimates of VE  
239 of PPV23 against IPD in the 5 years following administration in adults <65y of 54%, decreasing  
240 to 36% for 65-74y and 30% for 75y+ [17].

241  
242 **PCV and PPV vaccine impact model**  
243 We developed a cohort model to simulate the risk for IPD in adults >55y in all four countries.  
244 Time steps in the model were set at 1 year. Age-dependent all-cause mortality was set to match  
245 observed population demographics of older adults living without HIV in all countries, and age-  
246 dependent IPD risks were set to match fitted IPD incidence in respective countries and years. We  
247 calculated the vaccine preventable number of IPD cases as the lifetime number of cases averted  
248 through vaccinating 100% of adults at the specified age for vaccination under the scenarios of  
249 age-dependency on initial VE and waning VE. We estimated the efficiency of the alternative  
250 strategies by reporting the number of age cohort individuals needed to vaccinate (or number of  
251 doses needed to administer to age cohort) in order to prevent a case.

252

253 Sensitivity analysis assessed the influence of age-dependent initial VE on vaccine impact. All  
254 analyses were conducted using R language v4.1.1, with data and code available through GitHub  
255 <https://github.com/deusthindwa/optimal.age.targeting.pneumo.vaccines>.

256

## 257 **Ethical approval**

258 In Brazil, no patient consent is required since data are obtained through the National  
259 Epidemiological Surveillance approved by the Scientific Committee of the Instituto Adolfo Luiz  
260 (CTC 61-M/2020). In England, the UK Health Security Agency (UKHSA) has legal permission,  
261 provided by Regulation 3 of The Health Service Regulations 2002, to monitor the safety and  
262 effectiveness of vaccines for national surveillance of communicable diseases  
263 (<http://www.legislation.gov.uk/ukxi/2002/1438/regulation/3/made>). In Malawi, the study  
264 protocol was approved by Malawi's National Health Sciences Research Committee (protocol  
265 867), Kamuzu University of Health Sciences College of Medicine Research Ethics Committee  
266 (COMREC) (P-01/08/609 and P-09/09/826), and the University of Liverpool Research Ethics  
267 Committee (RETH490). Individual patient informed consent was not required for the use of  
268 publicly available anonymised routine samples as per COMREC guidelines 5-6. In South Africa,  
269 ethical approval to conduct laboratory-based and enhanced surveillance was obtained from the  
270 Health Research Ethics Committee (Human), University of Witwatersrand (M140159) and  
271 individual patient consent was obtained for clinical data collection at enhanced surveillance sites.  
272 Ethical approval for this study was granted by the London School of Hygiene and Tropical  
273 Medicine (25787).

274


## 275 **Results**

## 276 **Population demographics and IPD burden**

277 Of the 27.7 million (m) older adults ( $\geq 55$ y) in Brazil, 16.5m in England, 66,589 in Blantyre  
278 Malawi, and 6.9m in South Africa, the proportion of older adults aged 55y to  $<65$ y was 51.3%,  
279 51.0% and 53.8% in Brazil, Malawi and South Africa, substantially higher than the 39.1% in  
280 England. During the study period, Brazil (2015-2017), England (2016-2019), Malawi (2016-  
281 2019) and South Africa (2015-2018) reported 559, 13,971, 19, 537 IPD cases in adults  $\geq 55$ y  
282 equivalent to an average annual number of cases of 186.3, 4,658.0, 4.8 and 134.3, respectively.  
283 Of these in the  $\geq 55$ y, 44.5%, 19.9%, 62.5%, and 47.9% were in  $<65$ y olds. Cases caused by  
284 PCV13 serotypes accounted for 61.4% (343/559), 21.0% (2,936/13,971), 41.0% (8/19), and  
285 32.8% (176/537) of all IPD in Brazil, England, Malawi and South Africa, and PPV23 serotypes  
286 for 97.9% (547/559), 72.5% (10,126/13,971), 94.8% (18/19), and 73.2% (393/537), respectively  
287 (Fig 1).

288  
289 The exponential model fitted the increase in IPD incidence with age well. The estimated IPD  
290 incidence in 85y was higher than in 55y olds by 2.48-fold (95% confidence interval [95% CI]:  
291 2.13-2.83) in Brazil, 2.19-fold (95% CI: 0.14-4.51) in Malawi, and 2.25-fold (95% CI: 1.88-  
292 2.62) in South Africa. In England the incidence increased more steeply to 11.00-fold (95% CI:  
293 10.90-11.40) higher in 85y than 55y (Fig 1).

294  
295 While the estimated number of IPD cases declined with age in Brazil, Malawi and South Africa,  
296 it increased in England. On the other hand, age-specific IPD incidence of total IPD incidence  
297 (age-scaled IPD incidence) increased with age in all settings irrespective of serotype, and with  
298 high uncertainty in Malawi due to small case numbers (Fig S4, Fig S5).



300 Figure 1. Population demographics and invasive pneumococcal disease (IPD) burden. (Left  
 301 panel) Among individuals who are aged  $\geq 55$ y, the proportion/share in annual age groups in  
 302 Brazil, England, Malawi and South Africa as estimated from their national censuses, based on  
 303 five years rolling average smoothed population counts to control for demographic stochasticity;  
 304 (Middle panel) Number of IPD cases in five year age bands in older adults stratified by serotype  
 305 in Brazil (2015-2017), England (2016-2019), Blantyre Malawi (2016-2019) and South Africa  
 306 (2015-2018), reported from at least four years post-infant PCV introduction in each country.  
 307 (Right panel) Serotype-specific reported and predicted IPD incidence per 100,000 population  
 308 between 55y and 90y in Brazil, England, Malawi and South Africa. The black circle represents  
 309 estimated IPD cases per 100,000 population, the vertical line through the circle represents a 95%  
 310 uncertainty interval in estimated IPD case number, the curve line is the exponential model fit and  
 311 the ribbon represents a bootstrapped 95% confidence interval for the fitted line. The red and

312 black points for England represent estimated IPD cases in the presence and absence of PPV23  
313 vaccination, respectively.


314

### 315 **Optimal age for vaccination**

316 The optimal age for vaccination, the age of a single-dose vaccination that could prevent most  
317 IPD cases, is attained when vaccines are given earlier in the considered age range in the  
318 LIC/MIC setting, but not for England (Fig 2). In the base scenario with rapid waning of PPV23  
319 VE, we found that the highest proportion of all IPD cases could be preventable if adults aged 55y  
320 are vaccinated in Brazil (30.5%, 22.4-43.3), in Malawi (31.0%, 7.7-96.6), and in South Africa  
321 (20.0%, 13.7-28.7), and if adults aged 70y are vaccinated in England (13.7%, 10.8-17.4)  
322 compared to a scenario without vaccination (Table S1). Also, In the base scenario with rapid  
323 waning VE, higher proportion of all preventable cases are estimated for using PCV20 vs PPV23  
324 relative to a scenario without vaccination in Brazil (61.3%, 42.7-89.2) vs (30.1%, 20.6-43.5),  
325 Malawi (64.5 %, 13.0-92.2) vs (28.5%, 5.7-73.3), and South Africa (53.1%, 39.7-73.2) vs  
326 (19.8%, 13.0-29.2) among adults aged 55y, and in England (27.2%, 21.6-34.5) vs (13.6%, 10.4-  
327 17.6) among adults aged 70y, respectively (Table S2). Furthermore, higher proportion of IPD  
328 cases are preventable under slow vs rapid waning of PPV23 VE among adults aged 55y in Brazil  
329 (40.7%, 29.0-57.1) vs (30.1%, 20.6-43.5), Malawi (38.6 %, 8.0-77.2) vs (28.5%, 5.7-73.3), South  
330 Africa (26.4%, 18.2-38.3) vs (19.8%, 13.0-29.2), and among adults aged 70y in England (17.5%,  
331 13.8-22.0) vs (13.6%, 10.4-17.6), respectively (Table S3).


332





333 Figure 2. The impact of routine pneumococcal vaccination in older adults aged  $\geq 55$  years old (y).  
 334 The expected absolute number of total IPD cases averted for the rest of age cohort lifetime by  
 335 vaccinating every older adult in the age cohort stratified by country and vaccine product, under  
 336 the scenario of age-independent initial vaccine efficacy/effectiveness (VE) and waning VE in  
 337 Brazil, England, Malawi and South Africa. The lines represent cohort model mean estimates and  
 338 the shaded ribbon represents 95% bootstrap confidence intervals for the mean estimates. The X  
 339 corresponds to the optimal age for pneumococcal vaccination. In Brazil, Malawi and South  
 340 Africa, most cases are preventable at age 55y whereas in England this is achieved at age 70y.  
 341  
 342 The optimal age for vaccinating the lowest number of individuals with single dose pneumococcal  
 343 vaccine to prevent a reported case of IPD (vaccination efficiency) is estimated to differ by  
 344 country, vaccine product or waning VE assumption (Fig 3). In a base case scenario with rapid  
 345 waning of PPV23 VE, optimal age for vaccination efficiency is achieved through vaccination at

346 60y in Malawi 684 (244-2,009), 65y in Brazil 10,283 (8,165-13,162), and 75y in South Africa  
 347 3,643 (3,004-4,555) and at 80y in England 352 (287-438) (Table S4).  
 348



349 Figure 3. The efficiency of routine pneumococcal vaccination in older adults aged  $\geq 55$  years old  
 350 (y). The number of individuals needed to vaccinate to prevent a case in each age of vaccination,  
 351 stratified by country and vaccine product, under assumptions of age-independent initial vaccine  
 352 efficacy/effectiveness (VE) and waning VE in Brazil, England, Malawi and South Africa. The  
 353 lines represent cohort model mean estimates and the shaded ribbon represents 95% bootstrap  
 354 confidence intervals for the mean estimates. The X represents the optimal age for efficiency of  
 355 pneumococcal vaccination. Efficiency of vaccination varies by waning VE assumption and  
 356 country reflecting sensitivity in reported invasive pneumococcal disease cases.

357

358 **Sensitivity analyses**

359 If a scenario of age-dependent initial VE is considered in a sensitivity analysis, vaccine impact  
360 (total cases averted) remains maximum at 55y in Brazil, Malawi, and South Africa irrespective  
361 of vaccine product and assumption of waning VE as was the case with the base case scenario of  
362 age-independent initial VE. In contrast, optimal age for vaccination drops to 60y in England (Fig  
363 S6). In this scenario, the optimal age of vaccination efficiency is achieved by vaccination of 60y  
364 in Brazil, Malawi and South Africa, irrespective of vaccine product or assumptions of waning  
365 VE. In England, efficiency is achieved in 60y age cohort for PCV20 and PPV23 irrespective of  
366 waning VE assumption, and in 80y or 85y for PCV13's and PCV15's slow or fast waning VE,  
367 respectively (Fig S7).

368

## 369 **Discussion**

370 We have assessed the optimal age-targeting for a single-dose PCV/PPV vaccination against VT-  
371 IPD in older adults  $\geq 55$ y in Brazil, England, Malawi, and South Africa and find that vaccinating  
372 at 55y in considered LIC/MICs maximises preventable burden of IPD while vaccination at 70y is  
373 optimal in England. These findings suggest that the optimal age for vaccination may differ  
374 between countries and is driven by population age demographic, age-dependent IPD incidence  
375 and VE. Our findings were robust across pneumococcal vaccine products, and to alternative  
376 assumption on waning of VE.

377  
378 The increasing incidence of IPD in older adulthood is outweighed by many more individuals in  
379 the fifties in LIC/MICs. The different age population structure in England, with a higher  
380 proportion of  $\geq 55$ y in the middle to older adult ages, results in the optimal age for vaccination  
381 peaking later at 70y. The optimal age of vaccination in England also aligns with results from an  
382 Australian study that explored the role of timeliness in the cost-effectiveness of older adult  
383 vaccination and found that most deaths and hospitalisations were prevented if PCV13 was given  
384 to 70y, a peak age of prevented burden before dropping in remaining older ages [15].

385  
386 The age with lowest number of individuals needed to vaccinate to prevent a case (optimal age of  
387 vaccination efficiency) differed by country, vaccine product or assumption of waning VE, in part  
388 reflecting the differences in sensitivity of IPD surveillance and the complex interplay between  
389 different factors influencing vaccination efficiency. Although this finding accounts for life  
390 expectancy, it does not consider quality-adjusted life-years losses due to IPD which could shift

391 the optimal age of vaccination efficiency downwards because more individuals affected by IPD  
392 would be added to the fifties than elderly.  
393  
394 Our cohort model prediction of more preventable cases in all settings with the use of PCV20 vs  
395 PPV23 under similar conditions reflects higher efficacy/effectiveness of PCV20 than PPV23 [2].  
396 Moreover, a larger number of IPD preventable cases by PCV20 than lesser-valent PCVs  
397 underlines the importance of additional serotypes 8, 10A, 11A, 12F and 15B and/or 22F, 33F  
398 covered by PCV20 in the remaining IPD burden in the mature infant-PCV era [10]. Generally,  
399 other disease endpoints including non-bacteraemic pneumonia may also be important for vaccine  
400 choice e.g., PCV13 is shown to be more efficacious in preventing VT non-bacteraemic  
401 pneumonia than PPV23 (46% vs 21%) [2], and if included in this analysis, it may likely heighten  
402 PCV13 impact to similar levels or higher than PPV23 in England, albeit with higher vaccine  
403 cost. With the likely upcoming use of PCV15 and PCV20 in infants in the near future [39], the  
404 vaccine preventable fraction of adult disease is likely to diminish correspondingly because of the  
405 indirect effects of such infant programme, and thus reducing the benefit of adult programmes  
406 that target the same serotypes as those targeted in infants. On the other hand, PCV21 targets most  
407 serotypes not targeted by PPV23 or PCV20 [40], which could likely improve tackling the  
408 remaining burden of pneumococcal disease in older adults, in the long absence of vaccines that  
409 target surface proteins common to all serotypes [41]. However, for LICs/MICs, PCV15, PCV20  
410 and PCV21 may likely not be accessible soon due to their high initial costs.  
411  
412 Of note, we excluded older adults with HIV because they typically are considered separately for  
413 pneumococcal vaccination because of their high risk of disease before they reach old age.

414 However, inclusion of older adults with HIV may likely elevate IPD burden in early older  
415 adulthood because of their huge presence in early than late adulthood due to survival bias  
416 thereby re-enforcing vaccinating early in older adulthood, particularly in Malawi and South  
417 Africa where adult HIV prevalence is relatively high [29]. In this analysis, the contribution of  
418 PCVs' indirect protection from older adults to overall vaccine impact is ignored because older  
419 adults have low carriage rates unlike children who are the main transmitters, and the use of  
420 PPV23 does not protect against carriage and therefore unlikely to generate substantial herd  
421 immunity [42]. Sequential dosing of vaccine regimens was not modelled, although PCV15  
422 followed by PPV23 is now recommended by the advisory committee on immunisation practices  
423 (ACIP) in the United States [43]. This sequential regimen would likely generate higher impact  
424 than a single dose of PCV20 or PPV23, albeit with cost-effectiveness implications that need  
425 further research, particularly in LICs [2].

426

427 PCVs and PPV23 are reported to have limited efficacy/effectiveness against serotype 3  
428 pneumococcal carriage and disease [44], and our inclusion of serotype 3 IPD cases in this  
429 analysis imply that our vaccine impact estimates are likely biased upwards. PPV23 is already in  
430 use in  $\geq 65$ y in England [17], and we show in this analysis that the effects of PPV23 use have  
431 reduced the original IPD burden (Fig 1), and without adjusting for the current PPV23 vaccination  
432 programme, our optimal age for vaccination in this country may be overestimated. Reported IPD  
433 case data in LMICs are usually incomplete or under-ascertained due to limited resources e.g.  
434 only 19 IPD cases were reported in Malawi and even less so when stratified by age and serotype  
435 [3]. Thus, our results should be cautiously interpreted. Despite potential biases of case  
436 underreporting, it seems reasonable to assume that underreporting is consistent across adult age

437 groups, such that a relative change in IPD incidence by age to identify optimal age-targeting  
438 vaccination is less likely affected.

439

440 In conclusion, the optimal age-targeting for vaccination is largely driven by population age  
441 demographic, age-dependent IPD incidence and VE. In contrast to the typical use in adults in  
442 HICs, we find that pneumococcal vaccination in 55y older adults in LIC/MICs may be the most  
443 effective strategy in reducing the IPD burden among older adults without HIV, although  
444 affordability, cost-effectiveness and infant vaccination plans will also need to be considered when  
445 designing a strategy to protect older adults against pneumococcal disease.

446

447 **Acknowledgements**

448 We thank all the individuals working in respective invasive pneumococcal disease (IPD)  
449 surveillance and laboratory management teams in the four countries for providing important data  
450 on IPD isolates and related causing serotypes. DT, KCJ, SF NF, RSH, and TDS are supported by  
451 the National Institute for Health Research (NIHR) Global Health Research Unit on Mucosal  
452 Pathogens (MPRU) where RSH is a NIHR Senior Investigator. In addition, SF is supported by a  
453 Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society. We  
454 would like to thank Stephen Gordon of Liverpool School of Tropical Medicine for insightful  
455 discussion and feedback at the initial stage of this work.

456

457 **Author contributions**

458 Conceptualization; DT, SC, SF, EM, PM, NA.

459 Data curation; DT, JK, SM, TDS, ZAC, NFY, SCGA, MCdCB.

460 Formal analysis; DT, SC, SF.

461 Funding acquisition; DT, NF, SL, RSH, CC, MCdCB, SF.

462 Investigation; DT, SC, JK, AvG, SW, SM, TDS, EM, PM, NA, ZAC, NFY, KJ, NF, SCGA, SL,  
463 RSH, CC, MCdCB, SF.

464 Methodology; DT, SC, NF, SL, RSH, CC, MCdCB, SF

465 Project administration; JK, AvG, SW, SM, TDS, ZAC, NFY, KJ, NF, SCGA, SL, RSH, CC,  
466 MCdCB.

467 Resources; DT, NF, SL, RSH, CC, MCdCB, SF.

468 Software; DT, SC.

469 Supervision; SF, NF



470 Validation; SC, JK, AvG, SW, SM, TDS, EM, PM, NA, ZAC, NFY, KJ, NF, SCGA, SL, RSH,

471 CC, MCdCB, SF.

472 Visualization; DT, SC.

473 Writing - original draft; DT, SC, SF.

474 Writing - review & editing; DT, SC, JK, AvG, SW, SM, TDS, EM, PM, NA, ZAC, NFY, KJ,

475 NF, SCGA, SL, RSH, CC, MCdCB, SF.

476 All authors read and approved the final manuscript.

477

#### 478 **Data availability**

479 An R script that was used to analyse the datasets and aggregated data are available in the GitHub  
480 repository <https://github.com/deusthindwa/optimal.age.targeting.pneumo.vaccines>.

481

#### 482 **Declaration of interests**

483 The authors declare no competing interests.

484

#### 485 **Role of the funding source**

486 A project grant from the National Institute for Health and Care Research (NIHR) Global Health

487 Research Unit on Mucosal Pathogens (MPRU) is supported using UK aid from the UK

488 Government (Grant 16/136/46). The views expressed in this publication are those of the

489 author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

490 The MLW Clinical Research Programme is supported by a Strategic Award from the Wellcome,

491 UK. This research was funded in whole, or in part, by the Wellcome Trust [Grant number

492 208812/Z/17/Z]. For the purpose of open access, the author has applied a CC BY public

493 copyright licence to any Author Accepted Manuscript version arising from this submission. The  
494 funders had no role in study design, collection, analysis, data interpretation, writing of the report  
495 or in the decision to submit the paper for publication. The corresponding author and senior  
496 authors had full access to the study data, and together, had final responsibility for the decision to  
497 submit for publication  
498

## 499 **References**

- 500 1. Wahl B, O'Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, et al. Burden of  
501 *Streptococcus pneumoniae* and *Haemophilus influenzae* type b disease in children in the era  
502 of conjugate vaccines: global, regional, and national estimates for 2000–15. *Lancet Glob*  
503 *Health*. 2018;6: e744–e757. doi:10.1016/S2214-109X(18)30247-X
- 504 2. Department of Immunization, Vaccines and Biologicals. WHO | SAGE Yellow Book for  
505 October 2020 [Internet]. Geneva, Switzerland: WHO; 2020 Oct p. 20. Available:  
506 [http://www.who.int/immunization/sage/meetings/2020/october/presentations\\_background\\_](http://www.who.int/immunization/sage/meetings/2020/october/presentations_background_docs/en/)  
507 [docs/en/](http://www.who.int/immunization/sage/meetings/2020/october/presentations_background_docs/en/)
- 508 3. Deloria Knoll M, Bennett JC, Garcia Quesada M, Kagucia EW, Peterson ME, Feikin DR, et  
509 al. Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease  
510 Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement  
511 and Distribution Estimation (PSERENADE) Project. *Microorganisms*. Multidisciplinary  
512 Digital Publishing Institute; 2021;9: 742. doi:10.3390/microorganisms9040742
- 513 4. Bonnave C, Mertens D, Peetermans W, Cobbaert K, Ghesquiere B, Deschodt M, et al.  
514 Adult vaccination for pneumococcal disease: a comparison of the national guidelines in  
515 Europe. *Eur J Clin Microbiol Infect Dis*. 2019;38: 785–791. doi:10.1007/s10096-019-  
516 03485-3
- 517 5. Hurley D, Griffin C, Young M, Scott DA, Pride MW, Scully IL, et al. Safety, Tolerability,  
518 and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults  
519 60 to 64 Years of Age. *Clin Infect Dis*. doi:10.1093/cid/ciaa1045
- 520 6. CDC Advisory Committee on Immunization Practices (ACIP). Etr for PCV15 use among  
521 adults ≥65 years old | CDC [Internet]. 27 Jan 2022 [cited 8 Feb 2022]. Available:  
522 <https://www.cdc.gov/vaccines/acip/recs/grade/pneumo-PCV15-PPSV23-age-based-etr.html>
- 523 7. Flasche S, Hoek AJV, Goldblatt D, Edmunds WJ, O'Brien KL, Scott JAG, et al. The  
524 Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While  
525 Sustaining Herd Immunity in High-Income Countries. *PLOS Med*. 2015;12: e1001839.  
526 doi:10.1371/journal.pmed.1001839
- 527 8. von Gottberg A, de Gouveia L, Tempia S, Quan V, Meiring S, von Mollendorf C, et al.  
528 Effects of Vaccination on Invasive Pneumococcal Disease in South Africa. *N Engl J Med*.  
529 2014;371: 1889–1899. doi:10.1056/NEJMoa1401914
- 530 9. Bar-Zeev N, Swarthout TD, Everett DB, Alaerts M, Msefula J, Brown C, et al. Impact and  
531 effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of  
532 vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi,  
533 2006–18: prospective observational time-series and case-control studies. *Lancet Glob*  
534 *Health*. Elsevier; 2021;9: e989–e998. doi:10.1016/S2214-109X(21)00165-0
- 535 10. Garcia Quesada M, Yang Y, Bennett JC, Hayford K, Zeger SL, Feikin DR, et al. Serotype  
536 Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10/13 Period:

- 537 Findings from the PSERENADE Project. *Microorganisms*. Multidisciplinary Digital  
538 Publishing Institute; 2021;9: 738. doi:10.3390/microorganisms9040738
- 539 11. Swarthout TD, Fronterre C, Lourenço J, Obolski U, Gori A, Bar-Zeev N, et al. High  
540 residual carriage of vaccine-serotype *Streptococcus pneumoniae* after introduction of  
541 pneumococcal conjugate vaccine in Malawi. *Nat Commun*. Nature Publishing Group;  
542 2020;11: 2222. doi:10.1038/s41467-020-15786-9
- 543 12. Thindwa D, Pinsent A, Ojal J, Gallagher KE, French N, Flasche S. Vaccine strategies to  
544 reduce the burden of pneumococcal disease in HIV-infected adults in Africa. *Expert Rev*  
545 *Vaccines*. Taylor & Francis; 2020;0: 1–8. doi:10.1080/14760584.2020.1843435
- 546 13. VACFA. Immunization Schedules - Africa | Vaccines for Africa [Internet]. 13 Apr 2018  
547 [cited 27 Aug 2020]. Available: <http://www.vacfa.uct.ac.za/immunization-schedules-africa>
- 548 14. Matanock A. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent  
549 Pneumococcal Polysaccharide Vaccine Among Adults Aged  $\geq 65$  Years: Updated  
550 Recommendations of the Advisory Committee on Immunization Practices. *MMWR Morb*  
551 *Mortal Wkly Rep*. 2019;68. doi:10.15585/mmwr.mm6846a5
- 552 15. Chen C, Wood JG, Beutels P, Menzies R, MacIntyre CR, Dirmesropian S, et al. The role of  
553 timeliness in the cost-effectiveness of older adult vaccination: A case study of  
554 pneumococcal conjugate vaccine in Australia. *Vaccine*. 2018;36: 1265–1271.  
555 doi:10.1016/j.vaccine.2018.01.052
- 556 16. Andrade AL, Minamisava R, Policena G, Cristo EB, Domingues CMS, Brandileone MC de  
557 C, et al. Evaluating the impact of PCV-10 on invasive pneumococcal disease in Brazil: A  
558 time-series analysis. *Hum Vaccines Immunother*. Taylor & Francis; 2016;12: 285–292.  
559 doi:10.1080/21645515.2015.1117713
- 560 17. Djennad A, Ramsay ME, Pebody R, Fry NK, Sheppard C, Ladhani SN, et al. Effectiveness  
561 of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive  
562 Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in  
563 England and Wales. *EClinicalMedicine*. 2019;6: 42–50. doi:10.1016/j.eclinm.2018.12.007
- 564 18. Cohen C, Mollendorf C von, Gouveia L de, Lengana S, Meiring S, Quan V, et al.  
565 Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive  
566 pneumococcal disease in South African children: a case-control study. *Lancet Glob Health*.  
567 2017;5: e359–e369. doi:10.1016/S2214-109X(17)30043-8
- 568 19. Choi YH, Andrews N, Miller E. Estimated impact of revising the 13-valent pneumococcal  
569 conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: A modelling study.  
570 *PLOS Med*. 2019;16: e1002845. doi:10.1371/journal.pmed.1002845
- 571 20. Brandileone M-CC, Almeida SCG, Minamisava R, Andrade A-L. Distribution of invasive  
572 *Streptococcus pneumoniae* serotypes before and 5 years after the introduction of 10-valent  
573 pneumococcal conjugate vaccine in Brazil. *Vaccine*. 2018;36: 2559–2566.  
574 doi:10.1016/j.vaccine.2018.04.010

- 575 21. Andrews NJ, Waight PA, George RC, Slack MPE, Miller E. Impact and effectiveness of  
576 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in  
577 the elderly in England and Wales. *Vaccine*. 2012;30: 6802–6808.  
578 doi:10.1016/j.vaccine.2012.09.019
- 579 22. Neto JT, Tannus Branco de Araujo G, Gagliardi A, Pinho A, Durand L, Fonseca M. Cost-  
580 effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São  
581 Paulo State, Brazil. *Hum Vaccin. Taylor & Francis*; 2011;7: 1037–1047.  
582 doi:10.4161/hv.7.10.15987
- 583 23. Boyles TH, Brink A, Calligaro GL, Cohen C, Dheda K, Maartens G, et al. South African  
584 guideline for the management of community-acquired pneumonia in adults. *J Thorac Dis*.  
585 2017;9: 1469–1502. doi:10.21037/jtd.2017.05.31
- 586 24. Wasmælia B, Nuno Duarte da Costa B, Marcia Maria Melo Q, Wadih Jo<sup>a</sup> Scandar N,  
587 Paulo Cøsar Morae S, David Wu T, et al. Censo Demografico 2010 Brazil. Características  
588 da população e dos domicílios Resultados do universo [Internet]. Rio de Janeiro, RJ -  
589 Brasil: Instituto Brasileiro de Geografi a e Estatística; 2011 pp. 1–270. Report No.: 3.  
590 Available:  
591 [https://biblioteca.ibge.gov.br/visualizacao/periodicos/93/cd\\_2010\\_caracteristicas\\_populaca](https://biblioteca.ibge.gov.br/visualizacao/periodicos/93/cd_2010_caracteristicas_populacao_domicilios.pdf)  
592 [o\\_domicilios.pdf](https://biblioteca.ibge.gov.br/visualizacao/periodicos/93/cd_2010_caracteristicas_populacao_domicilios.pdf)
- 593 25. Office for National Statistics UK. Estimates of the Population for the UK, England and  
594 Wales, Scotland and Northern Ireland 2017 [Internet]. Office for National Statistics; 2017  
595 Jun. Available:  
596 [https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationandmigration/estimates](https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationandmigration/populationandmigration/estimates)  
597 nestimates
- 598 26. National Statistical Office Malawi. Malawi Population and Housing Census 2018 [Internet].  
599 Zomba, Malawi, and Rockville, Maryland, USA: National Statistical Office Malawi; 2019  
600 May pp. 1–311. Report No.: 4. Available:  
601 [http://www.nsomalawi.mw/index.php?option=com\\_content%3Dcom\\_content%26view%3Darticle%2](http://www.nsomalawi.mw/index.php?option=com_content&view=article&id=26id%3D226:2018-malawi-population-and-housing-census%26catid%26catid%E2%80%89%3D%E2%80%89:reports%26Itemid%E2%80%89%3D%E2%80%89)  
602 [6id%3D226:2018-malawi-population-and-housing-](http://www.nsomalawi.mw/index.php?option=com_content&view=article&id=26id%3D226:2018-malawi-population-and-housing-census%26catid%26catid%E2%80%89%3D%E2%80%89:reports%26Itemid%E2%80%89%3D%E2%80%89)  
603 [census%26catid%26catid%E2%80%89%3D%E2%80%89:reports%26Itemid%E2%80%89%3D%E2%80%89](http://www.nsomalawi.mw/index.php?option=com_content&view=article&id=26id%3D226:2018-malawi-population-and-housing-census%26catid%26catid%E2%80%89%3D%E2%80%89:reports%26Itemid%E2%80%89%3D%E2%80%89)  
604 [2%80%896](http://www.nsomalawi.mw/index.php?option=com_content&view=article&id=26id%3D226:2018-malawi-population-and-housing-census%26catid%26catid%E2%80%89%3D%E2%80%89:reports%26Itemid%E2%80%89%3D%E2%80%89)
- 605 27. Statistics South Africa. South Africa Population Census 2011 [Internet]. Statistics South  
606 Africa; 2011. Available: [http://www.statssa.gov.za/?page\\_id=3992](http://www.statssa.gov.za/?page_id=3992)
- 607 28. World Bank Group. World Population Annual Growth [Internet]. 10 Aug 2021 [cited 10  
608 Aug 2021]. Available: <https://data.worldbank.org/indicator/SP.POP.GROW?>
- 609 29. Johnson L, Dorrington R. Thembisa Project - A Mathematical Model of South African HIV  
610 epidemic [Internet]. 8 Feb 2022 [cited 8 Feb 2022]. Available: <https://www.thembisa.org/>
- 611 30. Fox GA, Kendall BE. Demographic Stochasticity and the Variance Reduction Effect.  
612 *Ecology*. 2002;83: 1928–1934. doi:10.1890/0012-9658(2002)083[1928:DSATVR]2.0.CO;2

- 613 31. Chaguza C, Heinsbroek E, Gladstone RA, Tafatatha T, Alaerts M, Peno C, et al. Early  
614 Signals of Vaccine-driven Perturbation Seen in Pneumococcal Carriage Population  
615 Genomic Data. *Clin Infect Dis*. 2020;70: 1294–1303. doi:10.1093/cid/ciz404
- 616 32. Dwyer-Lindgren L, Cork MA, Sligar A, Steuben KM, Wilson KF, Provost NR, et al.  
617 Mapping HIV prevalence in sub-Saharan Africa between 2000 and 2017. *Nature*. 2019;570:  
618 189. doi:10.1038/s41586-019-1200-9
- 619 33. Wright LB, Hughes GJ, Chapman KE, Gorton R, Wilson D. Effectiveness of the 23-valent  
620 pneumococcal polysaccharide vaccine against invasive pneumococcal disease in people  
621 aged 65 years and over in the North East of England, April 2006–July 2012. *Trials*  
622 *Vaccinol*. 2013;2: 45–48. doi:10.1016/j.trivac.2013.09.004
- 623 34. Rudnick W, Liu Z, Shigayeva A, Low DE, Green K, Plevneshi A, et al. Pneumococcal  
624 vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada,  
625 1995–2011. *Vaccine*. 2013;31: 5863–5871. doi:10.1016/j.vaccine.2013.09.049
- 626 35. Rodríguez MAG, Gavín MAO, García-Comas L, Moreno JCS, Deorador EC, Carbajo  
627 MDL, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged  
628 60 years and over in the Region of Madrid, Spain, 2008–2011. *Eurosurveillance*. European  
629 Centre for Disease Prevention and Control; 2014;19: 20922. doi:10.2807/1560-  
630 7917.ES2014.19.40.20922
- 631 36. Bonten MJM, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al.  
632 Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults. *N Engl J*  
633 *Med*. 2015;372: 1114–1125. doi:10.1056/NEJMoa1408544
- 634 37. Patterson S, Webber C, Patton M, Drews W, Huijts SM, Bolkenbaas M, et al. A post hoc  
635 assessment of duration of protection in CAPiTA (Community Acquired Pneumonia  
636 immunization Trial in Adults). *Trials Vaccinol*. 2016;5: 92–96.  
637 doi:10.1016/j.trivac.2016.04.004
- 638 38. van Werkhoven CH, Huijts SM, Bolkenbaas M, Grobbee DE, Bonten MJM. The Impact of  
639 Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly. *Clin Infect*  
640 *Dis*. 2015;61: 1835–1838. doi:10.1093/cid/civ686
- 641 39. Senders S, Klein NP, Lamberth E, Thompson A, Drozd J, Trammel J, et al. Safety and  
642 Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the  
643 United States. *Pediatr Infect Dis J*. 2021;40: 944–951. doi:10.1097/INF.0000000000003277
- 644 40. Merck. Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for  
645 V116, the Company’s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the  
646 Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults. In:  
647 Merck.com [Internet]. [cited 10 Jul 2022]. Available: <https://www.merck.com/news/merck-announces-u-s-fda-has-granted-breakthrough-therapy-designation-for-v116-the-companys-investigational-21-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-invasive-pneumococ/>  
648  
649  
650

- 651 41. Weinberger DM, Harboe ZB, Shapiro ED. Developing Better Pneumococcal Vaccines for  
652 Adults. *JAMA Intern Med.* 2017;177: 303–304. doi:10.1001/jamainternmed.2016.8289
- 653 42. Flasche S, Lipsitch M, Ojal J, Pinsent A. Estimating the contribution of different age strata  
654 to vaccine serotype pneumococcal transmission in the pre vaccine era: a modelling study.  
655 *BMC Med.* 2020;18: 129. doi:10.1186/s12916-020-01601-1
- 656 43. Kobayashi M. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent  
657 Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the  
658 Advisory Committee on Immunization Practices — United States, 2022. *MMWR Morb*  
659 *Mortal Wkly Rep.* 2022;71. doi:10.15585/mmwr.mm7104a1
- 660 44. Linley E, Bell A, Gritzfeld JF, Borrow R. Should Pneumococcal Serotype 3 Be Included in  
661 Serotype-Specific Immunoassays? *Vaccines.* Multidisciplinary Digital Publishing Institute;  
662 2019;7: 4. doi:10.3390/vaccines7010004
- 663